Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Trial Profile

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Vemurafenib (Primary) ; Thyrotropin alfa
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 07 Jun 2016 Results of preliminary analysis (n=12) assessing efficacy of vemurafenib in patients with BRAF-mutant thyroid cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 25 Feb 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top